AZN.L लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 23:39):

Stats
आज की मात्रा	1.64M
औसत मात्रा	2.94M
बाजार मूल्य	186.80B
EPS	£0 ( 2024-04-24 )
अगली कमाई की तारीख	( £1.530 ) 2024-06-04
Last Dividend	£71.80 ( 2023-08-10 )
Next Dividend	£0 ( N/A )
P/E	37.31
ATR14	£7.95 (0.07%)

मात्रा सहसंबंध

लंबा: 0.07 (neutral)

छोटा: -0.06 (neutral)

Signal:(65.972) Neutral

AstraZeneca PLC सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

AstraZeneca PLC सहसंबंध - मुद्रा/वस्त्र

-0.70
( moderate negative )

-0.65
( weak negative )

-0.84
( strong negative )

-0.70
( moderate negative )

0.84
( strong )

AstraZeneca PLC वित्तीय

Annual	2023
राजस्व:	£45.81B
सकल लाभ:	£37.54B (81.95 %)
EPS:	£3.84

FY	2023
राजस्व:	£45.81B
सकल लाभ:	£37.54B (81.95 %)
EPS:	£3.84

FY	2022
राजस्व:	£44.35B
सकल लाभ:	£31.96B (72.06 %)
EPS:	£2.12

FY	2021
राजस्व:	£37.42B
सकल लाभ:	£24.98B (66.76 %)
EPS:	£0.0854

Financial Reports:

No articles found.

AstraZeneca PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£76.40 (N/A)	£0 (N/A)	£162.80 (N/A)	£0 (N/A)	£71.80 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

AstraZeneca PLC Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.82 - Stable (3.62%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	£10.50	1993-09-20
Last Dividend	£71.80	2023-08-10
Next Dividend	£0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	61	--
Total Paid Out	£3 651.80	--
Avg. Dividend % Per Year	1.07%	--
Score	4.42	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.82
Div. Directional Score	7.92	--

Next Divdend (Est)
(2024-07-01)

£70.63 Estimate 7.48 %

Dividend Stability

0.30 Very Poor

Dividend Score

4.42

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
1993	£10.50	1.75%
1994	£27.75	3.38%
1995	£29.00	3.38%
1996	£32.25	2.65%
1997	£36.00	2.24%
1998	£39.00	1.87%
1999	£42.20	1.65%
2000	£44.39	1.77%
2001	£47.56	1.41%
2002	£47.90	1.55%
2003	£43.95	1.98%
2004	£45.40	1.69%
2005	£56.20	2.98%
2006	£78.40	2.73%
2007	£88.30	3.18%
2008	£95.50	4.45%
2009	£140.80	5.04%
2010	£150.30	5.11%
2011	£168.60	5.64%
2012	£181.70	5.96%
2013	£179.70	6.05%
2014	£169.90	4.78%
2015	£182.50	3.98%
2016	£199.70	4.46%
2017	£219.10	4.94%
2018	£202.00	3.96%
2019	£218.70	3.70%
2020	£216.00	2.82%
2021	£202.20	2.72%
2022	£221.70	2.62%
2023	£0	0.00%
2024	£0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TYMN.L	Dividend Knight	2023-08-03	Annually	29	2.69%
MGCI.L	Dividend King	2023-08-03	Quarterly	6	3.54%
CTEC.L	Dividend Knight	2023-08-17	Semi-Annually	8	1.46%
SCP.L	Dividend Knight	2023-07-13	Semi-Annually	31	1.83%
HTG.L	Dividend King	2023-10-05	Semi-Annually	32	1.82%
BCPT.L	Dividend King	2023-09-14	Monthly	20	2.80%
WKP.L	Dividend Junior	2023-07-06	Annually	31	2.53%
NAIT.L	Dividend Knight	2023-07-20	Quarterly	53	2.33%
ECK.L	Dividend Knight	2023-09-21	Annually	14	0.93%
SOM.L	Dividend King	2023-09-21	Semi-Annually	18	5.37%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.133	1.500	7.34	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0619	1.200	7.94	9.52	[0 - 0.3]
returnOnEquityTTM	0.168	1.500	9.25	10.00	[0.1 - 1]
payoutRatioTTM	0.706	-1.000	2.94	-2.94	[0 - 1]
currentRatioTTM	0.886	0.800	-0.572	-0.458	[1 - 3]
quickRatioTTM	0.661	0.800	-0.820	-0.656	[0.8 - 2.5]
cashRatioTTM	0.271	1.500	9.60	10.00	[0.2 - 2]
debtRatioTTM	0.338	-1.500	4.37	-6.56	[0 - 0.6]
interestCoverageTTM	5.33	1.000	9.14	9.14	[3 - 30]
operatingCashFlowPerShareTTM	6.26	2.00	7.91	10.00	[0 - 30]
freeCashFlowPerShareTTM	3.73	2.00	8.13	10.00	[0 - 20]
debtEquityRatioTTM	0.923	-1.500	6.31	-9.46	[0 - 2.5]
grossProfitMarginTTM	0.820	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.184	1.000	8.32	8.32	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.281	1.000	9.55	9.55	[0.2 - 2]
assetTurnoverTTM	0.465	0.800	-0.230	-0.184	[0.5 - 2]
Total Score				11.02

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	36.99	1.000	6.36	0	[1 - 100]
returnOnEquityTTM	0.168	2.50	9.52	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	3.73	2.00	8.76	10.00	[0 - 30]
dividendYielPercentageTTM	1.189	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.26	2.00	7.91	10.00	[0 - 30]
payoutRatioTTM	0.706	1.500	2.94	-2.94	[0 - 1]
pegRatioTTM	-56.74	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.204	1.000	7.41	0	[0.1 - 0.5]
Total Score				4.82

AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.